Search results

Order by most recent / most popular / relevance

Results: 11-19 of 19

Procedures and licensing for the establishment of life sciences companies in China

McDermott Will & Emery
-
China
-
July 25 2011

Intricate rules and regulations govern the procedures and licensing of life sciences companies in China

China to adopt central procurement system for essential drugs at grass-roots hospitals

McDermott Will & Emery
-
China
-
December 22 2010

The General Office of the State Council of China recently released Guiding Opinions that aim to minimise distribution intermediaries and costs in order to reduce the price of essential drugs at grass-roots medical institutions

Wholly foreign-owned medical institutes no longer prohibited in China

McDermott Will & Emery
-
China
-
December 14 2010

The People's Republic of China recently eased its restrictions on foreign capital investment in the health care industry to promote private medical institutes and the establishment of wholly foreign-owned medical institutes

New Chinese health and pharmaceuticals regulations

McDermott Will & Emery
-
China
-
June 28 2010

Regulation by the Chinese Government of the health and pharmaceuticals industry generally follows a cyclical pattern: a major incident occurs that impacts the Chinese public and triggers government investigations, resulting in changes to the regulation or regulatory system to close the loopholes found in the old legal regime that allowed the incident to happen in the first place

China promulgates new regulations on pharmaceutical precursor chemicals

McDermott Will & Emery
-
China
-
June 23 2010

The Measures are intended to strengthen the administration of pharmaceutical precursor chemicals, avoid inflow of the chemicals to the illegal drug market and clarify the division of authority among relevant governmental departments

Liabilities for medical tort under PRC Tort Liability Law

McDermott Will & Emery
-
China
-
March 18 2010

The New Tort Liability Law of the People's Republic of China contains medical tort provisions that are of significance to medical institutions and their investors

China cracks down on commercial bribery to make medical products more affordable

McDermott Will & Emery
-
China
-
July 6 2009

In China, bribes are sometimes offered and accepted for the sale and procurement of pharmaceuticals, medical devices and medical paraphernalia (health care products

Opinions on strengthening the centralised procurement of drugs by medical institutions

McDermott Will & Emery
-
China
-
February 26 2009

Pharmaceutical enterprises, drug manufacturers and certain medical institutions in China must comply with strengthened rules regarding centralised online procurement of drugs

Chinese pharmaceutical and dietary supplement safety issues

McDermott Will & Emery
-
China
-
April 29 2008

Wu Zhen, a deputy director of China’s State Food and Drug Administration (SFDA) has noted that “serious incidents related to drug safety have been happening non-stop in China since 2006”

< back